Early Experience With Active Surveillance in Low-Risk Prostate Cancer Treated

Ji Yong Ha, Byung Hoon Kim, Choal Hee Park, Chun Il Kim
Department of Urology, Keimyung University School of Medicine, Daegu, Korea

Purpose: This study was conducted to describe our early experience with active surveillance (AS).

Materials and Methods: Between January 2008 and December 2012, 35 patients were treated with AS. Selection criteria included the following: Gleason score ≤6 with single positive core, clinical stage ≤T1c, prostate-specific antigen (PSA) ≤10 ng/mL, and unremarkable imaging results. On patient follow-up, we regularly measured PSA (every 3–6 months) and performed prostate biopsies (after 1 and 3 years).

Results: In the first year of follow-up, prostate biopsies were performed in 25 patients (13 patients, negative for cancer; 7 patients, Gleason score of 6 without progression; 5 patients, progression, treated with radical prostatectomy [RP]). In the third year of follow-up, prostate biopsies were performed in five patients (two patients, negative for cancer; one patient, Gleason score of 6 without progression; two patients, progression, treated with RP). Seven patients discontinued AS because of increased anxiety, and three patients were lost to follow-up. Overall, seven patients (28%) who experienced progression had a mean PSA doubling time (DT) of 7.54 years. Six patients had a PSA DT of more than 3 years, whereas one had a PSA DT of less than 3 years. This study was limited by its small sample size and short follow-up period.

Conclusions: PSA kinetics did not correlate with progression, which suggests that regular biopsies should still be performed. AS is an available treatment option for patients with a low risk of prostate cancer but should only be used in carefully selected patients.

Keywords: Need le biopsy; Prostate-specific antigen; Prostatic neoplasms; Watchful waiting

INTRODUCTION
Prostate cancer (PCa) is the second most frequently diagnosed cancer in males worldwide, and the incidence of PCa in Korean men is increasing [1,2]. With the onset of widespread prostate-specific antigen (PSA) testing, resulting in earlier detection of low-risk PCa, the incidence of clinically insignificant PCa has increased proportionately. The changing landscape of PCa has led to concerns regarding overdiagnosis and overtreatment.

Active surveillance (AS) is different from watchful waiting or delayed treatment in that active treatment will be initiated if disease progression becomes apparent at follow-up [3]. In recent years, AS has been more frequently offered as treatment for low-risk PCa [4,5], but this is not the case in Korea.

This study was conducted to describe our early experience with AS.

MATERIALS AND METHODS

1. Patient population
Clinical data were collected retrospectively from 35 patients were placed on AS as a treatment for PCa, between January 2008 and December 2012.
During follow-up, PSA was measured every 3–6 months. Follow-up biopsy scheme was done using the 12-core transrectal ultrasonography was done using the 12-core biopsy when the PSA doubling time (DT) was less than 3 years. Biopsy with DT was calculated by using the following formula: 

\[
\text{DT} = \frac{\log A - \log B}{2 \times \log \frac{A}{B}}
\]

where A is the initial PSA measurement, B is the final PSA measurement, and DT is the time difference between the calendar dates of the two PSA measurements [13].

**2. Criteria for AS**

The selection criteria for AS included a biopsy-derived Gleason score \(\leq 6\) in a single positive core, clinical stage \(\leq T1c\), PSA \(\leq 10\) ng/mL, and unremarkable magnetic resonance imaging (MRI) results [3, 6–12] (Table 1). Biopsy with transrectal ultrasonography was done using the 12-core biopsy scheme.

**3. Follow-up**

During follow-up, PSA was measured every 3–6 months, and prostate biopsies were performed at 1 and 3 years. The first-year confirmatory biopsy was intended to identify higher-grade cancer that had been missed in the previous biopsy [7].

**4. Prediction of disease progression**

Patients were reclassified as needing earlier prostate biopsy when the PSA doubling time (DT) was less than 3 years or suspicious clinical progression was observed. The PSA DT was calculated by using the following formula: 

\[
\text{DT} = \log A - \log B / 2 \times \log \frac{A}{B}
\]

where A is the initial PSA measurement, B is the final PSA measurement, and DT is the time difference between the calendar dates of the two PSA measurements [13].

**5. Criteria for intervention**

Definitive intervention was offered to those patients with Gleason score progression (an increase to 7 or greater) or an increase in the number of positive biopsy cores (to two or more than one lobe).

**RESULTS**

Overall, the mean age of the patients was 68 years (range, 55–80 years), the mean PSA was 7.38 ng/mL (range, 2.37–10.00 ng/mL), the mean prostate volume was 44.8 mL (range, 20.0–120.0 mL), the mean Gleason score was 4.97 (range, 3–6), the mean PSA density (PSAD) was 0.14 ng/mL (range, 0.05–0.5 ng/mL), and the mean PSA DT was 5.16 years. All of the patients had favorable risk. The mean follow-up duration was 32 months (range, 12–46 months) (Table 2).

**Table 1. Comparison of inclusion criteria for active surveillance by institution**

| Institution          | Clinical T stage | PSA (ng/mL) | Gleason score | Positive cores | Single core positivity | Other |
|----------------------|------------------|-------------|---------------|----------------|------------------------|-------|
| Johns Hopkins [3]    | ≤ T1c            | -           | ≤ 3+3=6       | ≤ 2            | ≤ 50%                  | PSAD ≤ 0.15 |
| Toronto University [7]| ≤ T2a            | ≤ 10.0      | ≤ 3+3=6       | -              | -                      | -     |
| UCSF [10]            | ≤ T2a            | ≤ 10.0      | ≤ 3+3=6       | ≤ 33%          | -                      | -     |
| ERSPC (PRIAS) [8]    | ≤ T2a            | ≤ 10.0      | ≤ 3+3=6       | ≤ 2            | -                      | PSAD ≤ 0.2 |
| MSKCC [11]           | ≤ T2a            | ≤ 10.0      | ≤ 3+3=6       | ≤ 3            | ≤ 50%                  | -     |
| Miami University [12] | ≤ T2a            | ≤ 10.0      | ≤ 3+3=6       | ≤ 2            | ≤ 20%                  | -     |
| Kagawa University [9] | ≤ T1c            | ≤ 20.0      | ≤ 3+3=6       | ≤ 2            | -                      | -     |
| Keimyung University  | ≤ T1c            | ≤ 10.0      | ≤ 3+3=6       | 1              | -                      | MRI: negative |

PSA, prostate-specific antigen; PSAD, PSA density; UCSF, University of California San Francisco; ERSPC, European Randomized Study of Screening for Prostate Cancer; MSKCC, Memorial Sloan Kettering Cancer Center; MRI, magnetic resonance imaging.

**Table 2. Characteristics of the patients**

| Variable                     | Value          |
|------------------------------|----------------|
| No. of patients              | 35             |
| Age (y)                      | 68 (55–80)     |
| PSA (ng/mL)                  | 7.38 (2.37–10.00) |
| Prostate volume (mL)         | 44.8 (20.0–120.0) |
| Gleason score                | 4.82 (3.00–6.00) |
| Follow-up duration (mo)      | 32 (12–46)     |

Values are presented as mean (range). PSA, prostate-specific antigen.

In the first year of follow-up, repeat biopsies were performed in 25 patients (71.4%) (13 patients, negative for cancer; 7 patients, Gleason score of 6 without progression; 5 patients, progression). All five patients with progression had a PSA DT of more than 3 years. Three of the five patients whose cancers progressed underwent radical prostatectomy, whereas the other patients requested a transfer to another hospital of their choice.

In the third year, repeat biopsies were performed in five patients (two patients, negative for cancer; one patient, Gleason score of 6 without progression; two patients, progression, treated with radical prostatectomy). Of the two patients with progression, one had a PSA DT of more than 3 years, whereas the other patient had a PSA DT of less than 3 years.

Before the scheduled first-year follow-up visit, three patients were lost to follow-up, whereas seven patients discontinued AS because of increased anxiety. Of these seven patients, four underwent radical prostatectomy, whereas the remaining three patients were treated with androgens based on their age and/or preference (Fig. 1).

Overall, eight patients had a PSA DT of less than 3 years and underwent prostate biopsy earlier. Only one of these patients had cancer progression. Of the seven patients with progression, six (85.7%) had a PSA DT of more than 3 years and one (14.3%) had a PSA DT of less than 3 years (Table 3). Seventeen patients (48.6%) discontinued AS, for several reasons (Table 4). The mean PSA DT was 7.54 years in the seven patients (28%) whose cancer progressed. Five pa-
TABLE 3. Stratification by baseline Gleason score and PSA doubling time

| Variable          | No. of patients | Progression |
|-------------------|-----------------|-------------|
|                   |                 | 1 y         | 3 y         |
| Gleason score     |                 |             |             |
| 3                 | 1               | 0           | 0           |
| 4                 | 4               | 1           | 0           |
| 5                 | 2               | 1           | 0           |
| 6                 | 28              | 3           | 2           |
| PSA doubling time (y) |     |             |             |
| >3                | 27              | 5           | 1           |
| ≤3                | 8               | 0           | 1           |
| Total             | 35              | 5           | 2           |

PSA, prostate-specific antigen.

FIG. 1. Flow chart of AS in 35 patients. AS, active surveillance; RP, radical prostatectomy; HT, hormone therapy; T/F, transfer.

TABLE 4. Reasons for termination on surveillance (n=35)

| Reason                      | No. of patients (%) |
|-----------------------------|---------------------|
| Radical prostatectomy       | 9 (25.7)            |
| Progression                 | 5 (14.3)            |
| Patients preference         | 4 (11.4)            |
| ADT (patients preference)   | 3 (8.6)             |
| Transferred (progression)   | 2 (5.7)             |
| Follow-up loss              | 3 (8.6)             |
| Total                       | 17 (48.6)           |

ADT, androgen deprivation therapy.

DISCUSSION

In the current PSA era, most patients with an initial diagnosis of localized PCa are considered to be the most likely to achieve a cure. Current treatment options for patients with localized PCa vary—radical prostatectomy, radiotherapy, cryotherapy, androgen ablation therapy, and AS [14].

Since first being introduced in 2002, AS—the concept of which is to cure clinically significant PCa prior to the development of advanced disease—is now an accepted treatment strategy for patients with PCa [4,6]. However, AS is still underused in the United States and is rarely used in Korea [15]. Patients and/or their physicians appear to want to treat PCa once it is diagnosed [6]. In our study, the 10 patients (28.6%) who discontinued AS did not have cancer progression and had a sufficient understanding of AS before it was initiated.

AS may reduce the risk of overtreatment of clinically insignificant PCa, but the individual risk of disease progression is difficult to determine. The first attempt to identify potentially low-risk PCa was described by Epstein et al. [16,17]. Their description focused on disease with clinical stage T1, a Gleason pattern score ≤3, a PSAD ≤0.1 ng/mL/g, two or fewer positive cores, and no cores with >50% involvement. For contemporary AS protocols, most clinicians incorporate the criteria of a low Gleason score (≤6), a low clinical stage (≤T2a), and low PSA values (≤10 ng/mL) with estimates of tumor volume from the biopsy when selecting patients [18]. We also used a similar but stricter criteria to select patients: clinical stage (≤T1c), one positive core (minimum of 12 cores taken), and negative imaging result. Most patients with low-risk PCa have normal ultrasonographic findings. MRI offers advantages over other imaging techniques for the detection of PCa [10]. Recently, MRI with various imaging techniques has improved tumor detection [19,20]. We think that a tumor undetected by MRI may belong to a more favorable risk group.

PSA kinetics have generally been used to predict disease progression. However, the PSA values over time that can predict disease progression during AS remain unknown [18]. Klotz et al. [7], the Johns Hopkins group [21], and the University of California San Francisco cohort [22] focused on PSA kinetics to determine the triggers indicating that AS should be discontinued. However, no correlations were
found between the PSA DT and adverse pathologic findings from the surveillance biopsy. In our study, the PSA DT was not associated with cancer progression on biopsy. The eight patients (22.8%) who had a PSA DT of < 3 years underwent biopsy earlier, but only one patient had cancer progression. Most patients who had a longer PSA DT did not experience cancer progression during AS. Before a patient decides to undergo definitive intervention, we believe that they should first elect to have a repeat biopsy and be reclassified.

The objective endpoint in an AS series is the number of patients remaining on surveillance after a specified time interval [18]. Several studies that have described the incidence of those who received active treatment during AS report that it ranges from 11% to 32% [7,8,11,23-25]. In our study, 17 patients (48.6%) discontinued AS for several reasons. However, only five patients (14.3%) ultimately received radical prostatectomy after progression. This fact is noteworthy. Patients in Korea want to be treated even if, based on the Epstein criteria, they have clinically insignificant PCa [26,27]. This is partly because of the health insurance system.

Kakehi et al. [9] demonstrated that, given the low mortality from PCa in Asian patients compared with Western patients, AS is a more appealing option for Asians. However, in our study, Korean PCa progression rates appear to be higher than those of other western institutions despite our implementation of stricter patient selection criteria. According to another study conducted in Korea, most patients with low-risk PCa detected on multicore prostate biopsy actually had pathologically upgraded or upstaged disease after examination of the radical prostatectomy specimen [28,29]. We think that AS is a reasonable option for low-risk PCa. However, this strategy is difficult to implement in Korea. In order to carry out AS more safely, new biomarkers and imaging tools are needed.

This study was limited by its small sample size and short follow-up period. Hence, a statistical analysis was not possible. Additional studies are needed to confirm the nature of low-risk PCa in Korea and to define the appropriate criteria for determining patient selection and cancer progression for AS.

### TABLE 5. Pathological findings in men with disease progression

| Follow-up at progression (y) | Biopsy findings at progression | Radical prostatectomy findings |
|-----------------------------|--------------------------------|--------------------------------|
|                             | PSA DT (y) | Positive cores | Gleason score | Extracapsular extension | Gleason score | Pathologic T stage |
| 1                           | 2.69       | 12.08          | 2             | 3+3=6                    | Absent        | 3+3=6 T2c           |
| 1                           | 3.31       | 7.56           | 2             | 3+3=6                    | Absent        | 3+3=7 T2e           |
| 1                           | 6.88       | 3.85           | 2             | 3+3=6                    | Absent        | 3+3=6 T2e           |
| 3                           | 5.66       | -2.77          | 1             | 3+4=7                    | Absent        | 3+4=7 T2a           |
| 3                           | 10.18      | 1.29           | 2             | 4+4=8                    | Present       | 4+3=7 T3a           |

PSA, prostate-specific antigen; PSA DT, prostate-specific antigen doubling time.

### CONCLUSIONS

PSA DT did not correlate with the progression of PCa, which suggests that regular biopsies should still be performed while monitoring for cancer progression. Interestingly, progression of PCa during AS resulted in the dissolution of the patient-doctor relationship and resulted in the patients transferring to another hospital. AS is a treatment option for low-risk PCa patients, but is a strategy that is difficult to implement in Korea.

### CONFLICTS OF INTEREST

The authors have nothing to disclose.

### REFERENCES

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91.
2. The statistics report: the incidence of cancer on 1999-2011 and the survival rate on 2012 [Internet]. Goyang: National Cancer Center; [cited 2012 Dec 1]. Available from: http://www.ncc.re.kr.
3. Carter HB, Walsh PC, Landis F, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-4.
4. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-9.
5. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007;4:692-8.
6. Lawrentschuk N, Klotz L. Active surveillance for favorable-risk prostate cancer: a short review. Korean J Urol 2010;51:665-70.
7. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
8. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
9. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008;38:122-8.
10. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F,
Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-70.

11. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Atypical histologic and staging and upstaging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008;180:1964-7.

12. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101:165-9.

13. Reymond J, Brewster S, Biers S. Oxford handbook of urology. PSA derivatives and kinetics: free-to-total, density, velocity, and doubling time. Oxford: Oxford University Press; 2010.

14. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A., Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:3217-22.

15. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-4.

16. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.

17. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:2001-5.

18. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.

19. Fradet V, Kurchanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010;256:176-83.

20. Afq A, Koh DM, Padhani A, van As N, Schaib SA. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011;108:1716-22.

21. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettelmann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-6.

22. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011;185:1656-60.

23. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-90.

24. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297-305.

25. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669-76.

26. Chung JS, Han BK, Jeong SJ, Hong SK, Byun SS, Choe G, et al. Pathologic outcome of unilateral low risk prostate cancers on multidrome prostate biopsy after radical prostatectomy. Korean J Urol 2008;49:5.974-8.

27. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 2010;105:1526-30.

28. Kim SC, Hong JH, Song K, Jeong IG, Song C, Kim CS, et al. Predictive factors for upgrading or upstaging in biopsy gleason score 6 prostate cancer. Korean J Urol 2009;50:836-42.

29. Ahn HJ, Ko YH, Jang HA, Kang SG, Kang SH, Park HS, et al. Single positive core prostate cancer in a 12-core transrectal biopsy scheme: clinicopathological implications compared with multifocal counterpart. Korean J Urol 2010;51:671-6.